SCHEMBL24089976

SCHEMBL24089976

COc1cccc(Nc2nc3ccc(Cl)cc3c(=O)n2-c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 1/20 0.48
DUSP3 P51452 1/20 0.48
PTPN5 P54829 1/20 0.48
PTPN11 Q06124 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23958167 0.88 PDE10A (0.44) TP53SMN1; SMN2MAPT
SCHEMBL24089978 0.87 TUBB4A (0.48) MEN1KMT2AUSP2SMN1; SMN2NPC1
SCHEMBL23065106 0.86 SMN1; SMN2 (0.50) TP53MEN1KMT2AUSP2ALDH1A1
SCHEMBL7612884 0.85 MEN1 (0.48) MEN1KMT2ATSHRSMN1; SMN2NPC1
SCHEMBL29623099 0.85 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2NPC1
SCHEMBL23065251 0.85 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2NPC1
SCHEMBL29623176 0.84 PDE10A (0.47) TP53SMN1; SMN2MAPT
SCHEMBL23064704 0.84 PDE10A (0.47) TP53SMN1; SMN2MAPT
SCHEMBL24407884 0.84 SMN1; SMN2 (0.44) SMN1; SMN2NPC1LMNAGAA
SCHEMBL24111015 0.84 MEN1 (0.47) TP53MEN1KMT2AUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL TP53 3934/4885MEN1 1124/4885KMT2A 1257/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 TP53 3625/4885MEN1 1282/4885KMT2A 967/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 TP53 3625/4885MEN1 1282/4885KMT2A 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.